The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Stefan Angermeier
No Relationships to Disclose
 
Juergen Debus
No Relationships to Disclose
 
Vera Heuer
No Relationships to Disclose
 
Nils Homann
Consulting or Advisory Role - Amgen; BMS GmbH & Co. KG; Lilly; MSD Oncology; SERVIER
 
Stephan Kanzler
No Relationships to Disclose
 
Stefan Kubicka
No Relationships to Disclose
 
Ruediger Liersch
No Relationships to Disclose
 
Sylvie Lorenzen
No Relationships to Disclose
 
Rolf Mahlberg
No Relationships to Disclose
 
Christian Mueller
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb Germany; Lilly
 
Lothar Mueller
Travel, Accommodations, Expenses - Octapharm; Pierre Fabre
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); PharmaMar (Inst); Roche (Inst)
 
Mark Reinwald
No Relationships to Disclose
 
Ulrich Ronellenfitsch
Consulting or Advisory Role - Fresenius Kabi
Research Funding - Intuitive Surgical (Inst)
Travel, Accommodations, Expenses - Fresenius Kabi
 
Ludwig Fischer von Weikersthal
No Relationships to Disclose
 
Ulas Tenekeci
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Immutep; Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma